Tenaya Therapeutics gets fast track designation for gene therapy TN-201
Clinical-stage biotechnology company Tenaya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, TN-201.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.